CUE Stock Overview
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cue Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$5.12 |
| 52 Week Low | US$1.30 |
| Beta | 2.01 |
| 1 Month Change | -23.37% |
| 3 Month Change | -46.59% |
| 1 Year Change | -67.21% |
| 3 Year Change | -88.26% |
| 5 Year Change | -81.83% |
| Change since IPO | -87.88% |
Recent News & Updates
Recent updates
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Apr 16
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?
Dec 30Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?
Aug 11Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug
Oct 04Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt
Sep 23News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat
Aug 26Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates
Aug 10Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%
May 18Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
May 12Cue Biopharma: A First Assessment
May 11Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 19Cue Biopharma: Too Long To Arrive At Topline Trial Data
Feb 23We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth
Nov 04Cue Biopharma doses first patient in trial for CUE-101 in head and neck cancer
Jun 10Companies Like Cue Biopharma (NASDAQ:CUE) Are In A Position To Invest In Growth
Jun 07Cue Biopharma's CUE-101 shows encouraging action in HPV+ head and neck cancer patients
May 10How Many Cue Biopharma, Inc. (NASDAQ:CUE) Shares Did Insiders Buy, In The Last Year?
Mar 21We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Feb 22Is Cue Biopharma, Inc. (NASDAQ:CUE) Popular Amongst Insiders?
Jan 27
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
Jan 07Reflecting on Cue Biopharma's (NASDAQ:CUE) Share Price Returns Over The Last Year
Dec 25Independent Director Aaron Fletcher Just Bought 3.9% More Shares In Cue Biopharma, Inc. (NASDAQ:CUE)
Nov 29We're Not Very Worried About Cue Biopharma's (NASDAQ:CUE) Cash Burn Rate
Nov 24Cue Biopharma (CUE) Investor Presentation - Slideshow
Nov 20Cue Biopharma EPS beats by $0.12, misses on revenue
Nov 17Shareholder Returns
| CUE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.8% | 0.4% | 1.0% |
| 1Y | -67.2% | 0.9% | 21.9% |
Return vs Industry: CUE underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: CUE underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CUE volatility | |
|---|---|
| CUE Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CUE's share price has been volatile over the past 3 months.
Volatility Over Time: CUE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 53 | Dan Passeri | www.cuebiopharma.com |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
Cue Biopharma, Inc. Fundamentals Summary
| CUE fundamental statistics | |
|---|---|
| Market cap | US$68.59m |
| Earnings (TTM) | -US$50.73m |
| Revenue (TTM) | US$5.49m |
12.5x
P/S Ratio-1.4x
P/E RatioIs CUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUE income statement (TTM) | |
|---|---|
| Revenue | US$5.49m |
| Cost of Revenue | US$38.10m |
| Gross Profit | -US$32.61m |
| Other Expenses | US$18.13m |
| Earnings | -US$50.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -593.93% |
| Net Profit Margin | -924.10% |
| Debt/Equity Ratio | 22.0% |
How did CUE perform over the long term?
See historical performance and comparison